Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Discovery Labs Anticipates Surfaxin Approval In 2008 For Respiratory Distress Syndrome

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm is resolving outstanding manufacturing issues with the synthetic surfactant, with plans to submit six-month stability data in a “complete response” to FDA.

You may also be interested in...



Discovery Enters Phase II Trial Of Surfaxin For Acute Respiratory Failure In Children

Firm takes next step in its goal to develop compound for wide range of respiratory problems in children and adults.

Discovery Enters Phase II Trial Of Surfaxin For Acute Respiratory Failure In Children

Firm takes next step in its goal to develop compound for wide range of respiratory problems in children and adults.

Discovery Labs Pulls Surfaxin Application In EU, Citing Manufacturing, Data Issues

The firm may be required to conduct additional clinical trials comparing lucinactant to the leading EU surfactant, Curosurf.

Topics

UsernamePublicRestriction

Register

PS065053

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel